Protocol Page


	Study ID (Protocol Number)
	CA223-001


	STUDY LOCATIONS*
	Dana Farber Cancer Institute Boston, MA 02215 Recruiting	Local Institution Boston, MA 02215 Not yet recruiting
	Local Institution Boston, MA 02215 Not yet recruiting	Memorial Sloan Kettering Cancer Ctr New York, NY 10065 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
	STUDY OVERVIEW
	The purpose of this study is to assess the safety and tolerability of BMS-986015 given in combination with BMS-936558 and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination, in subjects with advanced (metastatic and/or unresectable) solid tumors

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.